UK markets close in 1 hour 57 minutes

Marinus Pharmaceuticals, Inc. (61Y.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.4800+0.1100 (+8.03%)
As of 08:03AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 79.59M
Enterprise value 8.50M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.56
Price/book (mrq)4.83
Enterprise value/revenue 0.27
Enterprise value/EBITDA -0.07

Trading information

Stock price history

Beta (5Y monthly) 0.89
52-week change 3-83.79%
S&P500 52-week change 325.38%
52-week high 310.2000
52-week low 31.2000
50-day moving average 36.1906
200-day moving average 37.1529

Share statistics

Avg vol (3-month) 332
Avg vol (10-day) 379
Shares outstanding 554.93M
Implied shares outstanding 658.09M
Float 838.28M
% held by insiders 10.97%
% held by institutions 1105.82%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 323 Sept 2020

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-492.86%

Management effectiveness

Return on assets (ttm)-38.19%
Return on equity (ttm)-213.02%

Income statement

Revenue (ttm)30.99M
Revenue per share (ttm)0.58
Quarterly revenue growth (yoy)0.40%
Gross profit (ttm)N/A
EBITDA -126.13M
Net income avi to common (ttm)-141.4M
Diluted EPS (ttm)-2.4400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)150.29M
Total cash per share (mrq)2.75
Total debt (mrq)110.36M
Total debt/equity (mrq)658.26%
Current ratio (mrq)4.07
Book value per share (mrq)0.31

Cash flow statement

Operating cash flow (ttm)-118M
Levered free cash flow (ttm)-70.09M